Gold Waits As Global Markets Tempt The Unprepared Authored by Matthew Piepenburg via VonGreyerz.gold, 2026 is screaming “Uh-Oh” signals from nearly every sector and asset class with alarming yet eerily ignored clarity. This explains why the longer-term case for gold couldn’t be more obvious, regardless of natural price retracements in the near-term. In fact, if global financial conditions were not...
Gold Waits As Global Markets Tempt The Unprepared Authored by Matthew Piepenburg via VonGreyerz.gold, 2026 is screaming “Uh-Oh” signals from nearly every sector and asset class with alarming yet eerily ignored clarity. This explains why the longer-term case for gold couldn’t be more obvious, regardless of natural price retracements in the near-term. In fact, if global financial conditions were not otherwise so disturbing, this historical moment in time would be fascinating. But rather than just say this, let me show you. Rising Yields: The Most Misunderstood/Important Signal of 2026? For example, the $145T global bond market, which is $20T greater in size than the global stock market, remains less understood yet far more significant as an indicator . Specifically, this “boring” bond market is foretelling an historical sovereign debt crisis which is already playing out before way too many closed eyes. Yields on sovereign IOUs (British, American, German, Italian, Japanese, etc.) are climbing to the highest levels seen in decades. Three Reasons/Warnings for Rising Yields These yields rise when demand, price and, of course, TRUST in government bonds tank. This dying trust has a lot to do with global debt levels at over $360T and U.S. public debt levels reaching an embarrassing $40T marker, which effectively makes America one big “bad credit.” (1) Lenders Demand a Risk Premium Those with bad credit, of course, are charged a higher risk premium or “yield” by lenders, which explains why the yield on the U.S. 10Y has risen by 75 basis points in a matter of months despite a Fed which has yet to raise rates in 2026. The Fed, alas, is openly losing control of its bond market. This matters, because rising yields mean rising debt costs, which debt-addicted and debt-driven nations like the USA simply can’t control or afford anymore. (2) More Buyers than Sellers of USTs In addition to its fall from credit grace, the home of the world reserve currency and once sacred “return-free-r...
A fancy dress protest in Boston Harbor on Dec. 16, 1773; a gunshot in Sarajevo on June 28, 1914; a train arriving at the Finland Station in St. Petersburg on April 16, 1917: There are days that change the course of history — when a single incendiary event combusts with explosive forces that propel the world in a new direction. Bloomberg Opinion Columnist Adrian Wooldridge joined David Gura and Chr...
A fancy dress protest in Boston Harbor on Dec. 16, 1773; a gunshot in Sarajevo on June 28, 1914; a train arriving at the Finland Station in St. Petersburg on April 16, 1917: There are days that change the course of history — when a single incendiary event combusts with explosive forces that propel the world in a new direction. Bloomberg Opinion Columnist Adrian Wooldridge joined David Gura and Christina Ruffini on Bloomberg This Weekend to discuss how Brexit joined the list of days that have made an indelible mark on history. (Source: Bloomberg)
Morsa Images/DigitalVision via Getty Images Revolution Medicines ( RVMD ) reported Phase 3 clinical trial results showing its experimental cancer drug daraxonrasib significantly extended survival for patients with previously treated metastatic pancreatic cancer, a disease with few effective treatment options and one of the highest mortality rates among major cancers. The results, presented Sunday ...
Morsa Images/DigitalVision via Getty Images Revolution Medicines ( RVMD ) reported Phase 3 clinical trial results showing its experimental cancer drug daraxonrasib significantly extended survival for patients with previously treated metastatic pancreatic cancer, a disease with few effective treatment options and one of the highest mortality rates among major cancers. The results, presented Sunday during a plenary session at the American Society of Clinical Oncology's annual meeting and published simultaneously in The New England Journal of Medicine , met all primary and key secondary endpoints of the company's RASolute 302 study. According to the company, daraxonrasib reduced the risk of death by 60% compared with standard chemotherapy and more than doubled median overall survival. Revolution Medicines said median survival exceeded one year, a benchmark that company executives described as unprecedented in a Phase 3 trial for metastatic pancreatic cancer. The findings are important for investors because they represent the first Phase 3 success for daraxonrasib and could pave the way for regulatory submissions in a large, high-need cancer market. Positive results also provide validation for Revolution Medicines' broader strategy of targeting RAS-driven cancers, a field that has attracted significant investment from the biotechnology and pharmaceutical industries. A successful launch in pancreatic cancer could substantially expand the company's commercial prospects and strengthen confidence in its broader pipeline of RAS-targeted therapies. Pancreatic ductal adenocarcinoma, or PDAC, accounts for the vast majority of pancreatic cancer cases and is often diagnosed after it has already spread. Treatment options remain limited, particularly after patients have progressed following initial therapy. Daraxonrasib belongs to a new class of drugs known as RAS(ON) inhibitors. The treatment is designed to block active RAS signaling, a key driver of tumor growth in pancreatic can...
Wall Street has a comfortable habit when it comes to memory chips. For 40 years, analysts treated companies like Micron the way you'd treat a fishing boat: useful, occasionally lucrative, but always at the mercy of a tide nobody controls. Prices boom, everyone piles in, supply floods the market, ...
Wall Street has a comfortable habit when it comes to memory chips. For 40 years, analysts treated companies like Micron the way you'd treat a fishing boat: useful, occasionally lucrative, but always at the mercy of a tide nobody controls. Prices boom, everyone piles in, supply floods the market, ...
Getty Images Riley Exploration Permian ( REPX ) had some of the most profitable wells in the business in the last article . Now that commodity prices are considerably higher, this goes to a "license to print money". The company was already paying a dividend while also growing production and repaying debt. All that is about to get larger in the current commodity price environment. Stock Prices The ...
Getty Images Riley Exploration Permian ( REPX ) had some of the most profitable wells in the business in the last article . Now that commodity prices are considerably higher, this goes to a "license to print money". The company was already paying a dividend while also growing production and repaying debt. All that is about to get larger in the current commodity price environment. Stock Prices The stock price was already cheap as shown below even before the Iranian situation caused a rise in oil prices. Riley Exploration Permian Common Stock Price History And Key Valuation Measures (Seeking Alpha Website May 31, 2026) In what has largely been regarded as a rather frothy market with some excessive valuations, that low price-earnings ratio of a whole 5 is one of the lowest price-earnings ratios I can find for a solidly profitable company that does business in the United States. With a yield approaching the magic 5% mark, for me, this is beginning to look like a mouthwatering opportunity that is seldom found. It is practically a "given" that the higher commodity prices are going to lead to much higher earnings in the second quarter. By almost any measure this stock is dirt cheap. Skips Going Public Part of the reason for the low valuation is that this company only became Riley Exploration Permian through a reverse merger back in fiscal year 2021 . Reverse mergers are a popular tool because they skip the "going public" costs. However, for investors, managements that do this tend to produce extreme long-term outcomes (both ways). Furthermore, the acquisitions that built the company to where it is today came later still. So, there is not a lot of history of the company as it is currently composed despite the fact that the predecessor company has a fairly long stock price history. Oftentimes, the market wants a five-year history of the company in current form before really valuing it well. This company is getting to that market-imposed limit during a time of high commodity ...
Rasi Bhadramani/iStock via Getty Images This blog missed the mid-quarter on May 15th and decided to wait for month end to run the above returns. Not much that is surprising, other than smallcaps - both growth and value - have started to outperform. There are 1,778 names in the Russell 2000 per the LSEG data, and two sectors - financials and healthcare - sum to 745 names, or 40% of the market cap w...
Rasi Bhadramani/iStock via Getty Images This blog missed the mid-quarter on May 15th and decided to wait for month end to run the above returns. Not much that is surprising, other than smallcaps - both growth and value - have started to outperform. There are 1,778 names in the Russell 2000 per the LSEG data, and two sectors - financials and healthcare - sum to 745 names, or 40% of the market cap weight of the Russell. Given the move in the Russell, I thought more energy would be in the index, but the sector is less than 5% of the index. The annual return box found at the bottom half of the spreadsheet shows only the small-cap growth and value, and the mid-caps with 5-year returns that aren’t yet double digits. This last style-box update from mid-February 26 showed how the 5-year returns for small and mids, as well as the RSP and QQQE , were still single-digit returns. No surprise to anyone, growth is back in charge after the last 60 days, and even the laggard asset classes are starting to catch up. None of this is advice or a recommendation, but only an opinion. Past performance is no guarantee of future results. Morningstar is the source of all return data. Thanks for reading. Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.
Amazingly, shares of Micron Technology (NASDAQ: MU) have doubled over the past 48 days. As a result, this week the Boise, Idaho-based semiconductor manufacturer entered the rarefied $1 trillion club. Its market capitalization, as I write this, is about $1.04 trillion. That puts it, in terms of market value, above Walmart , Eli Lilly , and Berkshire Hathaway . Only about 14 publicly traded companie...
Amazingly, shares of Micron Technology (NASDAQ: MU) have doubled over the past 48 days. As a result, this week the Boise, Idaho-based semiconductor manufacturer entered the rarefied $1 trillion club. Its market capitalization, as I write this, is about $1.04 trillion. That puts it, in terms of market value, above Walmart , Eli Lilly , and Berkshire Hathaway . Only about 14 publicly traded companies worldwide are valued at $1 trillion or more. Micron's ascent to that level was the quickest in history. What could be even more amazing is that the company's share price might double again this year. While there's no guarantee of that, of course, it certainly seems possible. Here's why. Continue reading
Attack comes after Friday’s strike that killed three men as well, pushing death toll to more than 200 since last year The US military said on Saturday it had carried out a strike on a vessel in the eastern Pacific killing three men, the second strike in as many days. Officials with the US Southern Command said in a post on X that intelligence had confirmed that the vessel was transiting along “nar...
Attack comes after Friday’s strike that killed three men as well, pushing death toll to more than 200 since last year The US military said on Saturday it had carried out a strike on a vessel in the eastern Pacific killing three men, the second strike in as many days. Officials with the US Southern Command said in a post on X that intelligence had confirmed that the vessel was transiting along “narco-trafficking” routes in the eastern Pacific and engaged in “narco-trafficking” operations. Continue reading...
Key PointsKevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of around $24.99 per share, for a total transaction value of ~$137,000.
Key PointsKevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of around $24.99 per share, for a total transaction value of ~$137,000.